460 related articles for article (PubMed ID: 29131157)
1. Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies.
Maciocia PM; Wawrzyniecka PA; Philip B; Ricciardelli I; Akarca AU; Onuoha SC; Legut M; Cole DK; Sewell AK; Gritti G; Somja J; Piris MA; Peggs KS; Linch DC; Marafioti T; Pule MA
Nat Med; 2017 Dec; 23(12):1416-1423. PubMed ID: 29131157
[TBL] [Abstract][Full Text] [Related]
2. Pre-depletion of TRBC1+ T cells promotes the therapeutic efficacy of anti-TRBC1 CAR-T for T-cell malignancies.
Zhang C; Palashati H; Rong Z; Lin N; Shen L; Liu Y; Li S; Yu B; Yang W; Lu Z
Mol Cancer; 2020 Nov; 19(1):162. PubMed ID: 33218364
[TBL] [Abstract][Full Text] [Related]
3. TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers.
Nichakawade TD; Ge J; Mog BJ; Lee BS; Pearlman AH; Hwang MS; DiNapoli SR; Wyhs N; Marcou N; Glavaris S; Konig MF; Gabelli SB; Watson E; Sterling C; Wagner-Johnston N; Rozati S; Swinnen L; Fuchs E; Pardoll DM; Gabrielson K; Papadopoulos N; Bettegowda C; Kinzler KW; Zhou S; Sur S; Vogelstein B; Paul S
Nature; 2024 Apr; 628(8007):416-423. PubMed ID: 38538786
[TBL] [Abstract][Full Text] [Related]
4. Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies.
Ferrari M; Righi M; Baldan V; Wawrzyniecka P; Bulek A; Kinna A; Ma B; Bughda R; Akbar Z; Srivastava S; Gannon I; Robson M; Sillibourne J; Jha R; El-Kholy M; Amin OM; Kokalaki E; Banani MA; Hussain R; Day W; Lim WC; Ghongane P; Hopkins JR; Jungherz D; Herling M; Welin M; Surade S; Dyson M; McCafferty J; Logan D; Cordoba S; Thomas S; Sewell A; Maciocia P; Onuoha S; Pule M
Nat Commun; 2024 Feb; 15(1):1583. PubMed ID: 38383515
[TBL] [Abstract][Full Text] [Related]
5. Computational discovery of binding mode of anti-TRBC1 antibody and predicted key amino acids of TRBC1.
Saetang J; Sangkhathat S; Jangphattananont N; Khopanlert W; Julamanee J; Tipmanee V
Sci Rep; 2022 Feb; 12(1):1760. PubMed ID: 35110642
[TBL] [Abstract][Full Text] [Related]
6. Dimorphism in the T-cell receptor constant region affects T-cell function, phenotype and HIV outcome.
Kaewpreedee P; Boonrat P; Tansiri Y; Rowland-Jones SL; Hansasuta P
AIDS; 2019 Jul; 33(9):1421-1429. PubMed ID: 30932962
[TBL] [Abstract][Full Text] [Related]
7. Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry.
Horna P; Weybright MJ; Ferrari M; Jungherz D; Peng Y; Akbar Z; Tudor Ilca F; Otteson GE; Seheult JN; Ortmann J; Shi M; Maciocia PM; Herling M; Pule MA; Olteanu H
Blood Cancer J; 2024 Feb; 14(1):34. PubMed ID: 38424120
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Molecular Simulations and Deep Learning Prediction of Antibodies' Recognition of TRBC1 and TRBC2.
Zeng X; Wang T; Kang Y; Bai G; Ma B
Antibodies (Basel); 2023 Sep; 12(3):. PubMed ID: 37753972
[TBL] [Abstract][Full Text] [Related]
9. T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignancies.
Li F; Zhang H; Wang W; Yang P; Huang Y; Zhang J; Yan Y; Wang Y; Ding X; Liang J; Qi X; Li M; Han P; Zhang X; Wang X; Cao J; Fu YX; Yang X
Nat Commun; 2022 Jul; 13(1):4334. PubMed ID: 35882880
[TBL] [Abstract][Full Text] [Related]
10. Generation of V α13/β21+T cell specific target CML cells by TCR gene transfer.
Zha X; Xu L; Chen S; Yang L; Zhang Y; Lu Y; Yu Z; Li B; Wu X; Zheng W; Li Y
Oncotarget; 2016 Dec; 7(51):84246-84257. PubMed ID: 27713165
[TBL] [Abstract][Full Text] [Related]
11. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer.
Kim M; Pyo S; Kang CH; Lee CO; Lee HK; Choi SU; Park CH
PLoS One; 2018; 13(6):e0198347. PubMed ID: 29874279
[TBL] [Abstract][Full Text] [Related]
12. Flow cytometric evaluation of TRBC1 expression in tissue specimens and body fluids is a novel and specific method for assessment of T-cell clonality and diagnosis of T-cell neoplasms.
Berg H; Otteson GE; Corley H; Shi M; Horna P; Jevremovic D; Olteanu H
Cytometry B Clin Cytom; 2021 May; 100(3):361-369. PubMed ID: 32333725
[TBL] [Abstract][Full Text] [Related]
13. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.
Chen KH; Wada M; Pinz KG; Liu H; Lin KW; Jares A; Firor AE; Shuai X; Salman H; Golightly M; Lan F; Senzel L; Leung EL; Jiang X; Ma Y
Leukemia; 2017 Oct; 31(10):2151-2160. PubMed ID: 28074066
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
Allegra A; Innao V; Gerace D; Vaddinelli D; Musolino C
Blood Cells Mol Dis; 2016 Nov; 62():49-63. PubMed ID: 27865176
[TBL] [Abstract][Full Text] [Related]
15. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
16. CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.
Martyniszyn A; Krahl AC; André MC; Hombach AA; Abken H
Hum Gene Ther; 2017 Dec; 28(12):1147-1157. PubMed ID: 29207878
[TBL] [Abstract][Full Text] [Related]
17. An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells.
Knies D; Klobuch S; Xue SA; Birtel M; Echchannaoui H; Yildiz O; Omokoko T; Guillaume P; Romero P; Stauss H; Sahin U; Herr W; Theobald M; Thomas S; Voss RH
Oncotarget; 2016 Apr; 7(16):21199-221. PubMed ID: 27028870
[TBL] [Abstract][Full Text] [Related]
18. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
[TBL] [Abstract][Full Text] [Related]
19. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
20. Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies.
Chen KH; Wada M; Firor AE; Pinz KG; Jares A; Liu H; Salman H; Golightly M; Lan F; Jiang X; Ma Y
Oncotarget; 2016 Aug; 7(35):56219-56232. PubMed ID: 27494836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
